•  
  •  
  •  
  •  

2025-09-03 00:55:55

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes

Keywords Selected:  LaurusLabs

Research

  • Q4FY22 Result Update – Laurus Labs - ICICI Direct

Stock Report

  • Laurus Labs Ltd allotted 531.77 acres of land by the Government of Andhra Pradesh
  • Laurus Labs Ltd consolidated Q1 FY2026 PAT at Rs. 163.02 crores
  • Laurus Labs Limited approves 2nd interim dividend of Rs. 0.80
  • Laurus Labs Ltd posts Rs. 232.77 crores consolidated PAT in Q4FY25
  • Laurus Labs Limited receives EIR for API facility Unit-4
  • Laurus Labs Ltd Q3 FY2025 consolidated net profit jumps to Rs. 92.30 crores
  • Laurus Labs Limited invests in Laurus Bio Pvt Ltd
  • Laurus Labs Ltd posts Rs. 19.84 crores consolidated PAT in Q2FY25
  • Laurus Labs Inaugurates New State of the Art R&D Facility at IKP Knowledge Park
  • Laurus Labs concludes successful USFDA audit for API Manufacturing Facility at Hyderabad
  • Laurus Labs Ltd posts consolidated PAT of Rs. 12.51 crores in Q1 FY2025
  • Laurus Labs Limited receives EIR from USFDA for API facilities
  • Laurus Labs Limited recommends 2nd interim dividend of Rs. 0.40
  • Laurus Labs Ltd Q4 FY24 consolidated net profit up QoQ at Rs. 75.61 crores
  • Laurus Labs Limited forms JV company
  • Laurus Labs enters into Joint Venture Agreement with KRKA, Slovenia
  • Laurus Labs Ltd posts Rs. 23.14 crores consolidated PAT in Q3 FY2024
  • Laurus Synthesis Pvt Ltd receives Form 483 with 5 observations from USFDA
  • Laurus Labs Ltd Q2 FY2024 consolidated PAT up QOQ at Rs. 36.95 crores
  • ImmunoACT announces the approval of India's first CAR-T cell therapy, NexCAR19
  • Laurus Labs Limited acquires stake in Laurus Bio Private Limited
  • Laurus Labs Ltd posts slump in Q1FY24 consolidated PAT to Rs. 24.85 crores
  • Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets
  • Laurus Labs to increase stake in ImmunoACT to 33.86%

Latest Post

  • NDTV Board approves Rights Issue of upto INR 400 Crore
  • Cupid Limited Robust B2B Export Order Book & Encouraging International Order Pipeline
  • PNC Infratech Ltd emerges L1 bidder for AAI tender
  • ITCONS E-Solutions Limited bags contract
  • SDHI & Indian Maritime University sign MoU to launch maritime Centres of Excellence, specialized workforce training programmes


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024